Company intelligence / Profile preview

Suzhou Ruotai Pharmaceutical Technology

Suzhou, Jiangsu, Chinafmyykj.com ↗

Ownership: Private
Development stage: Commercial

Overview

Suzhou Ruotai Pharmaceutical Technology has a diversified pipeline with at least 14 programs spanning oncology, infectious disease, hematology/immune disorders. The company is developing therapeutics using modalities such as oncolytic viruses, cell therapies, microbiota-based approaches, mRNA drugs and AAV gene therapies. At least one program has reached the clinical stage for advanced cervical carcinoma; others are in preclinical or early development.

Therapeutic areas: OncologyHematologyImmunologyInfectious Diseases
Modalities: MicrobiotaOncolytic virusCell therapymRNA-based drugsAAV based gene therapy
Industry: Biotech

Drug pipeline

1 asset

RT201

Unknown

Beyond the preview

Go deeper on Suzhou Ruotai Pharmaceutical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Suzhou Ruotai Pharmaceutical Technology.

Explore the full profile